NCT05032833已完成1 期
A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Percentage of subjects with treatment emergent AEs (TEAES)
研究概览
简要总结
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •* Medically healthy based on medical records and study specific assessments
排除标准
- •* Presence or history of severe adverse reaction to any drug or drug excipient
研究组 & 干预措施
5-MeO-DMT arm
Experimental
干预措施: 5-MeO-DMT (Drug)
Placebo arm
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Percentage of subjects with treatment emergent AEs (TEAES)
时间窗: From screening through to the follow up visit, up to 65 days
次要结局
- Time to reach Cmax (tmax)(Day 1 (dosing day) and Day 2)
- Area under the plasma concentration- time curve(Day 1 (dosing day) and Day 2)
- Peak plasma concentration (Cmax)(Day 1 (dosing day) and Day 2)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of DM005 in Patients With Advanced Solid TumorsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckSolid CarcinomaNCT06515990Doma Biopharmaceutical（Suzhou）Co., Ltd.208
招募中
1 期
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in HumansDepressionNCT06671977Deepak C. D'Souza60
已完成
1 期
Pharmacokinetics of GH001 in Healthy VolunteersHealthy VolunteersNCT05163691GH Research Ireland Limited46
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)Neuropathic PainNCT03638869Relmada Therapeutics, Inc.24
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)Neuropathic PainNCT03637361Relmada Therapeutics, Inc.42